Polymorphic Forms of Manidipine
AssigneeCipla Limited
InventorsDharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Maruti Ganpati Ghagare
Life of this patent
Estimating the term…
Abstract
The invention relates to various new polymorphic forms of manidipine and pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of the polymorphic forms of manidipine and pharmaceutically acceptable salts thereof.
Claims38
A crystalline form of manidipine wherein the crystalline form of manidipine is selected from the group consisting of:
- Crystalline Form I of manidipine dihydrochloride, characterized by having an XRD pattern comprising peaks at 10.94, 13.50, 20.90, 21.14 and 24.86±0.2 °2θ or characterized by having an XRD pattern as shown in FIG. 1;
- Crystalline Form II of manidipine dihydrochloride, characterized by having an XRD pattern comprising peaks at 10.94, 22.02, 22.74 and 22.84±0.2 °2θ or characterized by having an XRD pattern as shown in FIG. 2;
- Crystalline Form III of manidipine dihydrochloride, characterized by having an XRD pattern comprising peaks at 9.06, 13.44, 20.98, 21.70, 21.80, 21.92, 22.80 and 24.42±0.2 °2θ or characterized by having an XRD pattern as shown in FIG. 3;
- Crystalline Form IV of manidipine dihydrochloride, characterized by having an XRD pattern comprising peaks at 12.58, 20.34 and 23.36±0.2 °2θ or characterized by having an XRD pattern as shown in FIG. 4;
- and
- Crystalline Form VI of manidipine base, characterized by having an XRD pattern comprising peaks at 5.08, 14.04, 15.40, 20.60 and 21.94±0.2 °2θ or characterized by having an XRD pattern as shown in FIG. 6.
(canceled)
6-7. (canceled)
(canceled)
12-13. (canceled)
(canceled)
18-19. (canceled)
(canceled)
(canceled)
Amorphous manidipine dihydrochloride (Form V).
29-30. (canceled)
(canceled)
(canceled)
Amorphous manidipine base (Form VII).
(canceled)
42-47. (canceled)
Dependencies are inferred from the claim text.